TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
In The News
2022 - 11 - 25
- Integrate HiCB and novel facility design to provide flexibility, speed, high quality at low cost
- Platform designed to simplified PD while minimizing tech transfer, scale up and manufacturing risks
- Showcase implementation strategy and plan
In Conversation | Xueming Qian – CEO & Co-Founder, Transcenta
Putting Biologics on the Fast Lane
Industrialization of Highly Intensified Connected/Continuous Biomanufacturing Platform (HiCB) to Address Patient and Business Needs
A CTO's Journey Into Continuous Biomanufacturing
TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors
BioPharm International：Moving Closer to End-to-End Continuous Bioprocessing
